“For the Q1, we expect total revenue to be in the range of $12.0M-$13.0M, reflecting the seasonal impact of tax refunds on our plasma business, with gross profit margins between 52.0% to 53.0% driven largely by an increased revenue contribution from our pharma patient affordability business. Operating expenses are expected to be between $7.0M-$7.5M, of which depreciation and amortization will be approximately $1.3M. This reflects investments largely required to support our pharma patient affordability growth. Adjusted EBITDA is expected to be in the range of $1.20M-$1.50M,” said Jeff Baker, Paysign CFO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYS:
- Fly Insider: NextNav, Akamai among week’s notable insider trades
- Paysign price target raised to $4 from $3 at DA Davidson
- Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
- Is PAYS a Buy, Before Earnings?
- Fly Insider: Crocs, Best Buy among week’s notable insider trades
